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esponsibility of InstAbstract Tubulin has been shown to be an effective target for the development of cytotoxic agents against
prostate cancer. Previously, we reported that Lx2-32c is an anti-tubulin agent with high binding afﬁnity to
tubulin. In this study, we investigated the potential of Lx2-32c to act as an effective cytotoxic agent in the
treatment of prostate cancer. MTT assays showed that Lx2-32c was cytotoxic to all tested prostate cancer cell
lines. The Lx2-32c-treated cells typically exhibited a rounded morphology associated with the onset of
apoptosis, as evidenced by immunocytochemical staining. Human prostate cancer cell lines treated with Lx2-32c
arrest in the G2/M phase of the cell cycle and the treatment is associated with an increased ratio of cells in
the sub-G0/G1 phase as determined by ﬂow cytometry. Furthermore, expression of the cleaved form of
poly (ADP-ribose) polymerase in prostate cancer cell lines treated with Lx2-32c was shown by Western
blotting assay. Xenograft implants of LNCaP and PC3-derived tumors in nude mice showed that Lx2-32c
treatment signiﬁcant inhibited tumor growth with effects equivalent to those of docetaxel. These ﬁndings
demonstrate the potential of Lx2-32c as a candidate antitumor agent for the treatment of prostate cancer.
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Lx2-32c against prostate cancer cells in vitro and in vivo 531. Introduction
Prostate cancer is the most common newly diagnosed cancer and the
second leading cause of cancer death in men in the United States1.
Androgen ablation remains the standard, ﬁrst-line treatment for
advanced, androgen-sensitive prostate cancer patients2. Even though
this treatment can result in the regression of prostate tumors,
unfortunately, most cases will subsequently progress to castration-
resistant prostate cancer (CRPC)2. Once patients develop CRPC,
cytotoxic-based chemotherapy offers one of the best strategies in terms
of a signiﬁcant survival beneﬁt3.
The use of anti-tubulin agents in the clinic was a milestone in
the treatment of CRPC with chemotherapy4. In the cell, tubulin
polymerizes to form long microtubule chains that make up the
cytoskeleton. As such, it is responsible for cell shape and mitosis,
and balanced microtubule dynamics are critical for cell survival.
Docetaxel was the ﬁrst anti-tubulin, cytotoxic chemotherapy drug
that showed a proven survival beneﬁt in the treatment of CRPC3.
It was consequently approved in 2004 by the FDA for the
treatment of CRPC. It has been well documented that docetaxel
binds tubulin to shift the microtubule equilibrium toward the
polymerized form, thus stabilizing microtubules, arresting cells in
the G2/M phase and inducing cell apoptosis5. In addition to
docetaxel, several other anti-microtubule agents, including caba-
zitaxel6, and epothilones7, have been employed as clinical
chemotherapy drugs in the treatment of CRPC. Because of the
clear therapeutic beneﬁt of anti-tubulin chemotherapy reagents in
treating CRPC, microtubules have been validated as a key target
for the research and development of novel anti-prostate
cancer drugs.
Lx2-32c (Fig. 1) is a novel taxane which was semi-synthesized
from cephalomannine8. We have previously shown that Lx2-32c
displays robust anti-cancer activity against several cancer types
in vitro and in vivo, including several paclitaxel-resistant can-
cers8,9. Based on its high binding afﬁnity to tubulin, which is
stronger than that of docetaxel10, we here explored the effect of
Lx2-32c on prostate cancer cell growth and its mechanism of
action, using validated in vivo and in vitro models.Figure 1 Chemical structures of Lx2-32c (A) and docetaxel (B).2. Methods
2.1. Materials
Lx2-32c is prepared by the State Key Laboratory of Bioactive
Substances and Functions of Natural Medicines at Institute of Materia
Medica (Chinese Academy of Medical Sciences) following the
previous protocol with a purity of 98% checked by HPLC8.
Docetaxel was purchased from Beijing Shongshuo Pharmaceutical
Technology Development Co., Ltd. (Beijing, China) with a purity of
99.5%. Lecithin was provided by Avanti Polar Lipids Inc., (Alaba-
ster, AL, USA). Cholesterol was purchased from Hubei KangBaoTai
Fine Chemicals Co., Ltd. (Wuhan, China). In experiments in vitro,
Lx2-32c and docetaxel were both dissolved in DMSO and stored at
20 1C for less than 1 month before use. The vehicle (DMSO) was
used as a control in all experiments at a maximum concentration of
0.1%. In the animal model, Lx2-32c liposomes were prepared
according to our previously published protocol11 and the docetaxel
injection solution was obtained from Qilu Pharmaceutical Co., Ltd.
(Jinan, China).2.2. Cell lines and cell culture
The human prostate cancer cell lines LNCaP, PC3 and Du145 and
the murine prostate cancer cell line RM-1 were purchased from the
Cell Culture Center at the Institute of Basic Medical Sciences,
Chinese Academy of Medical Sciences (Beijing, China). All cell
lines were cultured in RPMI-1640 media supplemented with 10%
fetal calf serum, penicillin (100 U/mL) and streptomycin
(100 mg/mL) (Gaithersburg, MD, USA), and incubated at 37 1C
in a humidiﬁed atmosphere containing 5% CO2. All cells were
harvested during the exponential growth phase.
2.3. Animals
The BALB/c nude mice were purchased from Beijing HFK
Bioscience Co., Ltd. (China). The animals were housed in a light-
and temperature-controlled room (21–22 1C; relative humidity 60–
65%) and maintained on a standard diet and water. All animal
studies comply with the ARRIVE guidelines, and all of the
experimental protocols were approved by the Committee of the
Ethics of Animal Experiments of Yantai University (Yantai,
China).
2.4. Cell viability assay
Cell viability was measured using an MTT assay according to our
previously published protocol12. Brieﬂy, the cells were seeded in a
96-well plate and incubated for 24 h, then treated with vehicle
control or Lx2-32c for 72 h. MTT solution (5 mg/mL) was added
into each well and incubated for another 2 h. DMSO was added
and the optical density was measured at 570 nm using a Molecular
Devices SpectraMax M5 (Sunnyvale, CA, USA). The 50%
inhibitory concentration (IC50) values were calculated.
2.5. Immunoﬂuorescence assays
The effect of Lx2-32c on microtubule morphology was visualized
by immunoﬂuorescence microscopy8. LNCaP and PC3 cells were
Table 1 Anti-proliferative proﬁles of Lx2-32c in prostate
cancer cell lines.
Cell line Sensitivity to
androgen
IC50 (nmol/L)
Docetaxel Lx2-32c
LNCaP Sensitive 4.4171.64 2.5770.71
PC3 Resistant 9.3772.30 2.9470.57
DU145 Resistant 11.8971.56 7.1771.28
RM-1 (Murine) Resistant 12.4572.89 4.2270.39
Guangyao Lv et al.54plated at 5 103 cells/well in a 24-well cell culture plate and
cultured overnight. After treatment for 24 h, the cells were ﬁxed
with cold 3.7% formaldehyde in phosphate-buffered saline (PBS)
for 10 min, and then incubated in 0.1% Triton X for 10 min. The
cells were incubated with anti–α-tubulin antibody (St. Louis, MO,
USA) at 37 1C for 1 h, and re-incubated with a FITC-conjugated
secondary antibody and then co-stained with Hoechst 33258
(10 μg/mL). The cells were observed under a ﬂuorescence micro-
scope (Tokyo, Japan), and representative images were taken of
cellular microtubules.
2.6. Cell cycle distribution analysis
A ﬂow cytometry assay was used to analyze the cell cycle
distribution as previously reported12. Brieﬂy, the cells were plated
into 6-well plates and incubated overnight. After treatment with
the test substances for 24 or 48 h, the cells were harvested and
ﬁxed in cold 70% ethanol overnight at 20 1C, and then washed
with PBS and stained with PI solution (20 mg/mL PI and
20 mg/mL RNaseA in PBS) for 30 min. The cell ﬂuorescence
was measured using FACS Cytometry (San Jose, CA, USA) and
the cell cycle distribution was analyzed.
2.7. Western blotting assay
Cells were treated with the test compounds for 48 h and then lysed
in RIPA cell lysis buffer. After centrifugation at 12,000 rpm using
the Eppendorf centrifuge (Model 5424, Germany) for 10 min at
4 1C, the cell lysates were subjected to SDS-PAGE and proteins
were transferred to PVDF membranes. The membranes were
blocked with 5% fat-free dried milk in TBST buffer for 2 h and
probed overnight at 4 1C with rabbit monoclonal antibodies
against poly ADP-ribose polymerase (PARP, Danvers, MA,
USA). After incubation with the corresponding secondary anti-
bodies, the proteins were visualized using an enhanced chemilu-
minescence system (Pittsburgh, PA, USA) according to the
manufacturer's instructions.
2.8. In vivo anti-cancer efﬁcacy studies
Male nude mice (4–6 weeks old, BALB/c) were introduced to
established xenograft tumor models of LNCaP and PC 3 according
to our previous protocols8. Brieﬂy, the tumors were isolated from
donor mice and implanted in the dorsa of recipient mice. When the
tumors reached an average volume of 100–300 mm3, the animals
were randomized into four groups (ﬁve or six per group):
(a) vehicle, (b) 10 mg/kg docetaxel injection, (c) 10 mg/kg Lx2-
32c liposomes, and (d) 20 mg/kg Lx2-32c liposomes. Treatments
were administered once every 3 days via intraperitoneal injection.
Tumor diameters and body weight were measured every 3 days
during treatment and the relative tumor volume was calculated.
At the end of the treatment, the mice were sacriﬁced and tumors
were removed. The rate of tumor inhibition in each treatment was
subsequently calculated based on the tumor weight.
2.9. Statistical analysis
Data were expressed as mean7SD. Statistical comparisons were
made by a one-way analysis of variance (ANOVA) test and
Po0.05 was considered statistically signiﬁcant.3. Results
3.1. Lx2-32c inhibits the proliferation of prostate cancer cells
The effect of Lx2-32c on the proliferation of prostate cancer cell
lines was detected by MTT assay, and the data showed that Lx2-
32c displayed robust cytotoxic activity against all the tested
prostate cancer cells, including the androgen-sensitive LNCaP cell
line and the androgen-resistant PC3, Du145 and RM-1 cell lines
(Table 1). The in vitro antitumor activity of Lx2-32c was stronger
than, or at least comparable to, that of docetaxel when assayed
under comparable conditions.3.2. Lx2-32c enhances microtubule polymerization in LNCaP
and PC3 cells
The effect of Lx2-32c treatment on cell microtubules was
examined by ﬂuorescence microscopy following immunoﬂuores-
cent staining of tubulin8. As shown in Fig. 2, the untreated LNCaP
and PC3 cells exhibited extensive microtubule formations in the
cytoplasm. However, following the treatment with Lx2-32c, most
cells exhibited an enlarged and rounded morphology with multiple
nuclei. After treatment, the cells were observed to include the
presence of DNA fragments, an indication of mitotic catastrophic
induction13. Normal metaphase plates with characteristic spindle
poles were rarely observed in Lx2-32c-treated cells, though they
were present within control-treated cultures.3.3. Lx2-32c arrests the cell in the G2/M phase and induces cell
apoptosis
To explore the effect of Lx2-32c on the cell cycle and cell
apoptosis, PI-stained cells were analyzed by ﬂow cytometry.
The data show that 20 nmol/L Lx2-32c treatment for 24 h was
sufﬁcient to arrest prostate cancer cells in the G2/M phase (Fig. 3).
Additionally, the ratio of cells in the sub-G0/G1 phase was
observed to increase dramatically after treatment with Lx2-32c
for 24 and 48 h (Fig. 4A).3.4. Lx2-32c induces the cleavage of PARP
To re-conﬁrm the effect of Lx2-32c on cell apoptosis, the
expression of cleaved (CL)-PARP, a biomarker of apoptosis14,
was detected by Western blot. As shown in Fig. 4B, treatment with
Figure 3 The effect of Lx2-32c on the cell cycle in LNcaP and PC3 cells. Cells were seeded into 6-well plates and treated with Lx2-32c
(20 nmol/L) or docetaxel (20 nmol/L) for 24 h. The cells were then subjected to ﬂow cytometry assay to determine the cell cycle (A) and
analyzed (B).
Figure 2 The effect of Lx2-32c on microtubules in LNcaP and PC3 cells. Cells were treated for 24 h with 0.1% DMSO, 10 nmol/L Lx2-32c or
10 nmol/L docetaxel. After ﬁxation, cells were incubated with an anti-α-tubulin antibody followed by a FITC-conjugated secondary antibody and
stained with Hoechst 33258 to visualize DNA. Images were overlaid electronically after cells were examined by ﬂuorescent microscopy and the
representative pictures were taken. Arrowheads indicate the altered microtubule morphology (scale bar: 20 μm).
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and PC3 cells, which is consistent with the ﬁndings of the ﬂow
cytometry assay.3.5. Lx2-32c possesses robust antitumor activity in vivo
To evaluate the antitumor activity of Lx2-32c in vivo, xenograft
models of LNCaP and PC3 were established. As shown in Fig. 5,Lx2-32c treatment was able to signiﬁcantly suppress the growth of
tumors derived from LNCaP and PC3 in a dose-dependent
manner. The observed antitumor potency of Lx2-32c was equiva-
lent to that for the docetaxel. As noted in Tables 2 and 3, the
growth of LNCaP and PC3 tumors was inhibited by more than
87% following the administration of Lx2-32c at 10 or 20 mg/kg.
An equivalent signiﬁcant decrease in body weight of the treated
animals was observed in both the Lx2-32c-treated and docetaxel-
treated mice.
Figure 5 Effect of Lx2-32c on the growth of LNCap tumor (A) and PC3 tumor (B) in nude mice. Tumor diameter was serially measured with a
vernier caliper, and the relative tumor volume was calculated and the growth curve was drawn. Vehicle (●); 10 mg/kg docetaxel (■); 10 mg/kg
Lx2-32c (▲); 20 mg/kg Lx2-32c (▼). **Po0.01 compared with control group.
Table 2 Inhibitory effects of Lx2-32c on the tumor growth of LNCaP in nude mice.
Group Dosage (mg/kg) Number Body weight (g)a Tumor weight (g)a Inhibitor rate (%)
Initial/end Initial End
Control 0 5/5 25.971.2 28.471.1 1.3470.67 0
Docetaxel 10 5/5 24.471.5 24.971.0* 0.0870.07* 94.4
Lx2-32c 10 5/5 24.671.7 25.271.5* 0.1970.10* 88.8
20 5/5 24.871.7 22.473.2* 0.0370.02* 97.9
aData are expressed as mean7SD (n¼5).
*Po0.01 compared with control.
Table 3 Inhibitory effects of Lx2-32c on the tumor growth of PC3 in nude mice.
Group Dosage (mg/kg) Number Body weight (g)a Tumor weight (g)a Inhibitor rate (%)
Initial/end Initial End
Control 0 5/5 25.672.6 28.171.5 1.3570.29 0
Docetaxel 10 6/5 25.172.7 24.872.9 0.1370.11* 90.1
Lx2-32c 10 6/6 26.572.4 26.372.5 0.1670.19* 87.8
20 6/6 24.471.5 21.471.3* 0.1470.15* 89.5
aData are expressed as mean7SD (n¼5 or 6).
*Po0.01 compared with control.
Figure 4 The effect of Lx2-32c on the apoptosis in LNcaP and PC3 cells. Cells were seeded into 6-well plate and treated with Lx2-32c (20 nmol/L)
or docetaxel (20 nmol/L) for 24 h. The cells were then subjected to ﬂow cytometry assay to determine the cell apoptosis (A) or the cells were
lysated to detect the CL-PARP by Western blot (B). *Po0.05 compared with control group. Doc, docetaxel; Lx, Lx2-32c.
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Microtubules are dynamic polymeric proteins that play a key role
in mitosis. They have been validated as one of the most important
and successful drug targets for the treatment of different malignant
tumors, including CRPC4,15. We report that Lx2-32c, a novel
microtubule-stabilizing agent, may act as a potential antineoplastic
compound against prostate cancer. By disrupting microtubule
dynamics, Lx2-32c was able to arrest human prostate cancer cell
lines in the G2/M phase and induce cell apoptosis. Furthermore,
Lx2-32c displayed robust antitumor activity in xenograft models
of prostate cancer in nude mice, indicating that Lx2-32c might be a
potential drug candidate for prostate cancer treatment.
Although androgen deprivation therapy is typically used as a
standard interventional treatment for advanced metastatic prostate
cancer, almost all patients eventually progress to CRPC2. Upon
reaching this stage, the microtubule-stabilizing agents, such as
docetaxel and cabazitaxel, have been proven to be the most effective
chemotherapy regimen16. The tubulin and the microtubule, therefore,
had been validated as the most potential drug target for the research
and development of novel agents against CRCP. Based on our
previous data that the binding afﬁnity of Lx2-32c to β-tubulin is
stronger than that of docetaxel10, we hypothesized that Lx2-32c might
exert a more powerful or at least comparable effect to docetaxel in the
treatment of prostate tumors. Indeed, in the MTT assay, Lx2-32c
displayed stronger cytotoxic activity against all the tested prostate
cancer cell lines, including androgen-sensitive LNCaP cells and
androgen-independent cells PC3, Du145 and RM-1, indicating that
Lx2-32c may be effective in targeting prostate cancer.
As a microtubule-stabilizing agent, Lx2-32c promotes micro-
tubule polymerization and inhibits its depolymerization in prostate
cancer cells. This was easily visualized using immunoﬂuorescence
staining. As shown in Fig. 2, the increase in the density of cellular
microtubules, as well as the obvious thick bundles of microtubules,
both of which are characteristic features of microtubule stabili-
zers17,18, were observed in both LNCaP cells and PC3 cells treated
with Lx2-32c. As microtubule dynamics were disrupted by the
presence of Lx2-32c in these cells, the mitotic spindles could not be
assembled correctly and cell mitosis was blocked. Consequently, the
cell cycle was disrupted and mitotic catastrophe was induced,
indicated by the presence of DNA fragments within the cells.
Flow cytometry was conducted to further analyze the effect
of Lx2-32c on the cell cycle. Consistent with our previous
ﬁndings using other cancer cell lines8, Lx2-32c arrested both
LNCaP and PC3 cells in the G2/M phase. Arresting the cell cycle
in this manner appears to induce apoptosis in these cells, as
demonstrated by the increased ratio of cells in the sub-G0/G1
phase following treatment with Lx2-32c. Similar results were
observed in the Western blot assay, in which CL-PARP, a well-
known apoptosis biomarker, was induced in Lx2-32c-treated cells.
Taken together, these ﬁndings show clearly that Lx2-32c is able to
disrupt microtubule dynamics by binding tubulin to arrest prostate
cancer cells in the G2/M phase and subsequently inducing
apoptosis.
Finally, the xenograft model of prostate cancer cells was
established using nude mice to explore the in vivo growth
inhibitory activity of Lx2-32c. To avoid any hypersensitivity
reactions induced by Cremophor EL castor oil19, the common
solvent for taxanes, Lx2-32c liposomes were prepared and used in
all animal studies11. The data show that Lx2-32c is able to inhibit
the growth of xenograft tumors from both prostate cancer cell lines
tested, and that the antitumor activity was comparable to that ofdocetaxel, the ﬁrst-line drug currently used to treat prostate cancer
in clinics. Both Lx2-32c and docetaxel were observed to exhibit
slight to moderate toxic effects to the animals based on the
evidence of weight loss in treated animals.5. Conclusions
In summary, our study demonstrates that Lx2-32c, a novel
microtubule-polymerizing agent, can arrest prostate cancer cells
in the G2/M phase and induce cell apoptosis by disrupting
microtubule dynamics, and that this compound displays robust
antitumor efﬁcacy in vivo. These ﬁndings indicate the potential of
Lx2-32c as a candidate antitumor agent for the treatment of
prostate cancer.
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